

Technology Advisory Committee Interests Register

Topic: SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dominic Pivonka	TAC A Committee Member	Indirect – Financial Interests	Dominic’s employer (AbbVie) markets a treatment in another disease area (Atopic Dermatitis) which is a competitor to one of the possible comparator technologies (dupilumab)	19/04/2024	It was agreed that Dominic’s declaration would not prevent her from participating in discussions on this appraisal.
Becky Pennington	TAC A Committee Member	Indirect – Financial	Becky received travel expenses from GSK for speaking at a symposium about spillovers/carers in Dec 2023.	18/04/2024	It was agreed that Becky's declaration would not prevent her from participating in discussions on this appraisal.
James Fotheringham	TAC A Committee Member	Indirect - Financial Interests	Astra-Zeneca - I am involved in systematic reviews relating to the management of hypertension, funded by AZ, paid to my organisation.	15/04/2024	It was agreed that James's declaration would not prevent him from participating in discussions on this appraisal.
Shuaib Nasser	Clinical Expert	Direct – Financial	I have undertaken consultancies for ALK including advice on sublingual immunotherapy products.	14/05/2024	It was agreed that Mr Shuaib’s declaration would not prevent him from

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dominic Pivonka	TAC A Committee Member	Indirect – Financial Interests	Dominic’s employer (AbbVie) markets a treatment in another disease area (Atopic Dermatitis) which is a competitor to one of the possible comparator technologies (dupilumab)	19/04/2024	It was agreed that Dominic's declaration would not prevent her from participating in discussions on this appraisal.
Becky Pennington	TAC A Committee Member	Indirect – Financial	Becky received travel expenses from GSK for speaking at a symposium about spillovers/carers in Dec 2023.	18/04/2024	It was agreed that Becky's declaration would not prevent her from participating in discussions on this appraisal.
			In the past 12 months I have given one paid lecture and sat on an advisory board for the company but not directly advised on the product under consideration.		participating in discussions on this appraisal.
Helen Evans-Howells	Patient Expert	Direct – Financial	<p>Helen lectured for ALK on Immunotherapy June 2022 and received £200.</p> <p>Nominated by Anaphylaxis UK Yes, Anaphylaxis UK received £12,380 from ALK for our Bee and Wasp Campaign which ran from May 2023 to September 2023.</p> <p>Trustee for Anaphylaxis UK and Chair of their Clinical and Scientific Panel</p>	14/05/2024	It was agreed that Ms Evans-Howells's declaration would not prevent her from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dominic Pivonka	TAC A Committee Member	Indirect – Financial Interests	Dominic’s employer (AbbVie) markets a treatment in another disease area (Atopic Dermatitis) which is a competitor to one of the possible comparator technologies (dupilumab)	19/04/2024	It was agreed that Dominic's declaration would not prevent her from participating in discussions on this appraisal.
Becky Pennington	TAC A Committee Member	Indirect – Financial	Becky received travel expenses from GSK for speaking at a symposium about spillovers/carers in Dec 2023.	18/04/2024	It was agreed that Becky's declaration would not prevent her from participating in discussions on this appraisal.
Amena Warner	Patient Expert	Indirect - Financial	<p>Amena personally does not financially gain but works for the charity Allergy UK who has corporate partnerships, so she has listed this as indirect interests.</p> <p>Funding from ALK;</p> <p>Nov 2010 – Dec 2010 £250</p> <p>Apr 2015 – Apr 2015 £5,000</p> <p>Oct 2016 – Oct 2016 £500 Plus travel exp.</p>	14/05/2024	It was agreed that Ms Warner's declaration would not prevent her from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dominic Pivonka	TAC A Committee Member	Indirect – Financial Interests	Dominic’s employer (AbbVie) markets a treatment in another disease area (Atopic Dermatitis) which is a competitor to one of the possible comparator technologies (dupilumab)	19/04/2024	It was agreed that Dominic's declaration would not prevent her from participating in discussions on this appraisal.
Becky Pennington	TAC A Committee Member	Indirect – Financial	Becky received travel expenses from GSK for speaking at a symposium about spillovers/carers in Dec 2023.	18/04/2024	It was agreed that Becky's declaration would not prevent her from participating in discussions on this appraisal.
			<p>Jan 2017 – Jan 2017 £500 Plus travel exp.</p> <p>Feb 2018 – May 2018 £3,250 plus VAT</p> <p>Sponsorship Agreement Jan 2022 Mar 2023 - £72,503</p> <p>This last amount was for a series of projects which included masterclasses for HCP’s, podcasts, video, article, online digital leaflet and top tips for managing asthma</p>		